Quick Answer
Anixa Biosciences Inc reported Net Income Loss of -$10.93 million for the year ending 2025.
- Anixa Biosciences Inc showed an increase of +13.0% in Net Income Loss from 2024 to 2025.
- This data is from Anixa Biosciences Inc's annual report (Form 10-K), filed with the SEC on January 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2011: -$1.53 million | Q2 2011: -$1.29 million | Q3 2011: -$1.77 million | Q4 2011: -$2.79 million | Q1 2012: -$886.1 thousand | Q2 2012: -$877.1 thousand | Q3 2012: -$629.1 thousand | Q4 2012: -$1.86 million | Q1 2013: -$2.09 million | Q2 2013: -$2.48 million | Q3 2013: -$2.58 million | Q1 2014: -$3.61 million | Q2 2014: -$3.25 million | Q3 2014: $411.0 thousand | Q1 2015: $3.75 million | Q2 2015: -$2.24 million | Q3 2015: -$1.60 million | Q1 2016: -$1.59 million | Q2 2016: -$1.27 million | Q3 2016: -$1.10 million | Q1 2017: -$3.60 million | Q2 2017: $160.5 thousand | Q3 2017: -$1.79 million | Q1 2018: -$1.84 million | Q2 2018: -$1.38 million | Q3 2018: -$5.48 million | Q3 2019: -$2.14 million | Q1 2020: -$2.59 million | Q2 2020: -$2.64 million | Q3 2020: -$2.56 million | Q1 2021: -$2.21 million | Q2 2021: -$2.40 million | Q3 2021: -$4.33 million | Q1 2022: -$3.83 million | Q2 2022: -$3.54 million | Q3 2022: -$2.75 million | Q1 2023: -$2.32 million | Q2 2023: -$2.29 million | Q3 2023: -$2.51 million | Q1 2024: -$3.26 million | Q2 2024: -$3.14 million | Q3 2024: -$3.28 million | Q1 2025: -$3.18 million | Q2 2025: -$2.79 million | Q3 2025: -$2.26 million | Q1 2026: -$2.57 million.
- Over the full 16 years of available data (2010 to 2025), Anixa Biosciences Inc's Net Income Loss has declined by 111.1%.
- Historical annual values: Fiscal year 2025: -$10.93 million | Fiscal year 2024: -$12.55 million | Fiscal year 2023: -$9.81 million | Fiscal year 2022: -$13.60 million | Fiscal year 2021: -$12.95 million | Fiscal year 2020: -$10.02 million | Fiscal year 2019: -$11.65 million | Fiscal year 2018: -$14.00 million | Fiscal year 2017: -$5.01 million | Fiscal year 2016: -$5.02 million | Fiscal year 2015: -$1.38 million | Fiscal year 2014: -$9.61 million | Fiscal year 2013: -$10.08 million | Fiscal year 2012: -$4.25 million | Fiscal year 2011: -$7.38 million | Fiscal year 2010: -$5.18 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: